Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4245293
Max Phase: Preclinical
Molecular Formula: C54H103N17O10S
Molecular Weight: 1182.59
Molecule Type: Small molecule
Associated Items:
ID: ALA4245293
Max Phase: Preclinical
Molecular Formula: C54H103N17O10S
Molecular Weight: 1182.59
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CSCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(C)=O)C(C)C)C(N)=O
Standard InChI: InChI=1S/C54H103N17O10S/c1-29(2)25-39(63-34(11)72)48(77)68-41(27-31(5)6)50(79)70-42(28-32(7)8)51(80)69-40(26-30(3)4)49(78)66-38(19-16-23-62-54(59)60)47(76)71-43(33(9)10)52(81)67-36(17-13-14-21-55)46(75)65-37(18-15-22-61-53(57)58)45(74)64-35(44(56)73)20-24-82-12/h29-33,35-43H,13-28,55H2,1-12H3,(H2,56,73)(H,63,72)(H,64,74)(H,65,75)(H,66,78)(H,67,81)(H,68,77)(H,69,80)(H,70,79)(H,71,76)(H4,57,58,61)(H4,59,60,62)/t35-,36-,37-,38-,39-,40-,41-,42-,43-/m0/s1
Standard InChI Key: HIQLTFVNXFEDJV-GMIRWQTLSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1182.59 | Molecular Weight (Monoisotopic): 1181.7795 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Dianati V, Kwiatkowska A, Couture F, Desjardins R, Dory YL, Day R.. (2018) Increasing C-Terminal Hydrophobicity Improves the Cell Permeability and Antiproliferative Activity of PACE4 Inhibitors against Prostate Cancer Cell Lines., 61 (18): [PMID:30180568] [10.1021/acs.jmedchem.8b01144] |
Source(1):